Labombarda Fabien, Saloux Eric, Brouard Jacques, Bergot Emmanuel, Milliez Paul
Caen CHU, Department of Cardiology, Caen, F-14000, France.
Caen CHU, Department of Cardiology, Caen, F-14000, France.
Respir Med. 2016 Sep;118:31-38. doi: 10.1016/j.rmed.2016.07.011. Epub 2016 Jul 15.
Cystic fibrosis is a complex multi-systemic chronic disease characterized by progressive organ dysfunction with development of fibrosis, possibly affecting the heart. Over the last four decades pathological, experimental, and clinical evidence points towards the existence of a specific myocardial involvement in cystic fibrosis. Multi-modality cardiac imaging, especially recent echocardiographic techniques, evidenced diastolic and/or systolic ventricular dysfunction in cystic fibrosis leading to the concept of a cystic fibrosis-related cardiomyopathy. Hypoxemia and inflammation are among the most important factors for heart involvement in cystic fibrosis. Cystic Fibrosis Transmembrane Regulator was found to be involved in the regulation of cardiomyocyte contraction and may also account for cystic fibrosis-related myocardial dysfunction. This review, mainly focused on echocardiographic studies, seeks to synthesize the existing literature for and against the existence of heart involvement in cystic fibrosis, its mechanisms and prognostic implications. Careful investigation of the heart function may be helpful for risk stratification and therapeutic decisions in patients with cystic fibrosis.
囊性纤维化是一种复杂的多系统慢性疾病,其特征为器官功能进行性障碍并伴有纤维化形成,心脏可能受累。在过去的四十年里,病理、实验和临床证据均表明囊性纤维化存在特定的心肌受累情况。多模态心脏成像,尤其是最近的超声心动图技术,证实了囊性纤维化患者存在舒张期和/或收缩期心室功能障碍,由此引出了囊性纤维化相关性心肌病的概念。低氧血症和炎症是囊性纤维化患者心脏受累的最重要因素。囊性纤维化跨膜传导调节因子被发现参与心肌细胞收缩的调节,也可能是囊性纤维化相关性心肌功能障碍的原因。本综述主要聚焦于超声心动图研究,旨在综合现有支持和反对囊性纤维化患者心脏受累及其机制和预后意义的文献。仔细评估心脏功能可能有助于囊性纤维化患者的风险分层和治疗决策。